fig1
From: A dimethylbromobenzene-cysteine stapled peptide dual inhibitor of the p53-MDM2/MDMX interactions
Figure 1. Wild-type p53 is a potential target for HCC therapy. A: The percentage of wild-type p53 in 867 HCC patients in The Cancer Genome Atlas; B and C: the Kaplan-Meier survival curves of overall survival and disease-free survival duration based on p53 expression in the mRNA level; D: the Schematic diagram for the mechanism of p53 function and its connection with MDM2 and MDMX; E-H: the Kaplan-Meier survival curves of overall survival and disease-free duration based on MDM2 and MDMX expression in the mRNA level. The receiver operating characteristic curve was used to define the cutoff, and log-rank analysis was used to test for significance. HCC: Hepatocellular carcinoma; PMI: p53-MDM2/MDMX inhibitor
